Drug Trial Radar · NCT06846320
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
315
Planned (sponsor's estimate)
Start
Apr 29, 2025
Primary completion
Nov 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Feb 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs. ABBV-932 is an investigational drug being developed for the adjunctive treatment of GAD. Participants will be randomly assigned to receive ABBV-932 or Placebo in addition to their currently prescribed ADTs. There is 1 in 3 chance of participants assigned to Placebo. Approximately 315 adult participants with GAD and inadequate response to ADTs will be enrolled in approximately 50 sites in the United States and Puerto Rico. Participants will receive oral capsules of ABBV-932 or matching placebo in addition to their prescribed ADT for 6 weeks and then will be followed for an additional 4 week follow-up period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Generalized Anxiety Disorder (GAD)
Interventions
ABBV-932Drug
Oral Capsule
Placebo for ABBV-932Drug
Oral Capsule
Antidepressant Therapy (ADT)Drug
Standard of care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 10 weeks
- Change from Baseline in the Hamilton Anxiety Scale (HAM-A) Total ScoreTime frame: Up to approximately 6 weeks
Locations
52 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama - Huntsville Regional Medical Campus /ID# 267818
Huntsville, Alabama · Recruiting
Ima Clinical Research Phoenix (Alea) /ID# 275737
Phoenix, Arizona · Recruiting
Noble Clinical Research /ID# 267952
Tucson, Arizona · Completed
Advanced Research Center /ID# 267874
Anaheim, California · Recruiting
Axiom Research /ID# 267814
Colton, California · Recruiting
Sun Valley Research Center /ID# 267864
Imperial, California · Recruiting
Synergy San Diego /ID# 267879
Lemon Grove, California · Recruiting
Alliance for Research Alliance for Wellness /ID# 267911
Long Beach, California · Recruiting
NRC Research Institute DTLA /ID# 267832
Los Angeles, California · Recruiting
Excell Research /ID# 267918
Oceanside, California · Recruiting
Inland Psychiatric Medical Group /ID# 268598
Temecula, California · Recruiting
Sunwise Clinical Research /ID# 267863
Walnut Creek, California · Recruiting
Connecticut Clinical Research - Cromwell /ID# 271241
Cromwell, Connecticut · Recruiting
Cns Healthcare - Jacksonville /ID# 268588
Jacksonville, Florida · Recruiting
Accel Research Sites Network - St. Pete /ID# 267821
Largo, Florida · Recruiting
K2 Medical Research, LLC /ID# 267841
Maitland, Florida · Recruiting
GMI Florida - Central Miami Medical Institute /ID# 267839
Miami, Florida · Recruiting
Allied Biomedical Res Inst Inc /ID# 267813
Miami, Florida · Recruiting
Apg Research /ID# 271707
Orlando, Florida · Recruiting
Psych Atlanta /ID# 267878
Marietta, Georgia · Recruiting
iResearch Savannah /ID# 267865
Savannah, Georgia · Recruiting
University of Chicago Medical Center /ID# 275131
Chicago, Illinois · Recruiting
Collective Medical Research /ID# 272015
Overland Park, Kansas · Recruiting
CenExel /ID# 267853
Gaithersburg, Maryland · Recruiting
Elixia - Springfield /ID# 267815
Springfield, Massachusetts · Recruiting
Psychiatric Care And Research Center /ID# 271701
O'Fallon, Missouri · Recruiting
Saint Charles Psychiatric Associates /ID# 271202
Saint Charles, Missouri · Recruiting
Arch Clinical Trials /ID# 267851
St Louis, Missouri · Recruiting
Ima Clinical Research Las Vegas (SMO/Network/Consortium) /ID# 275731
Las Vegas, Nevada · Recruiting
Duplicate_Oasis Clinical Research, LLC /ID# 267953
Las Vegas, Nevada · Completed
Princeton Medical Institute /ID# 267877
Princeton, New Jersey · Recruiting
Bio Behavioral Health /ID# 267919
Toms River, New Jersey · Recruiting
Integrative Clinical Trials /ID# 279519
Brooklyn, New York · Recruiting
New Hope Clinical Research - Inpatient unit /ID# 267810
Charlotte, North Carolina · Recruiting
Quest Therapeutics of Avon /ID# 267829
Avon Lake, Ohio · Recruiting
University Of Cincinnati Medical Center /ID# 271704
Cincinnati, Ohio · Recruiting
The Ohio State University /ID# 267924
Columbus, Ohio · Recruiting
Sooner Clinical Research /ID# 267881
Oklahoma City, Oklahoma · Recruiting
Lehigh Center for Clinical Research /ID# 267908
Allentown, Pennsylvania · Recruiting
Suburban Research Associates /ID# 267868
West Chester, Pennsylvania · Recruiting
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.